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OBJECTIVES We sought to compare the efficacy of primary angioplasty in diabetics versus nondiabetics and
to evaluate the relative benefits of angioplasty over thrombolytic therapy among diabetics.
BACKGROUND Primary angioplasty for myocardial infarction is at least as effective as thrombolytic therapy in
the general population. However, the influence of diabetic status on outcome after primary
angioplasty versus thrombolysis remains unknown.
METHODS Patients in the Global Use of Strategies To Open Occluded Arteries in Acute Coronary
Syndromes (GUSTO-IIb) Angioplasty Substudy were randomized to receive either primary
angioplasty or accelerated alteplase. The interaction of diabetic status (diabetics n 5 177,
nondiabetics n 5 961) and treatment strategy with the occurrence of the primary end point
(death, nonfatal reinfarction or nonfatal, disabling stroke at 30 days) was analyzed (power to
detect a 40% relative reduction in the primary end point with alpha 5 0.05 and beta 5 0.20).
Among patients who were randomized to and underwent primary angioplasty, procedural
success (defined as residual stenosis ,50% and TIMI grade 3 flow) was assessed based on
diabetic status.
RESULTS Compared with nondiabetics, diabetics had worse baseline clinical and angiographic profiles.
Despite more severe stenosis and poorer flow in the culprit artery, procedural success with
angioplasty was similar for diabetics (n 5 81; 70.4%) and nondiabetics (n 5 391; 72.4%).
Outcome at 30 days was better for nondiabetics randomized to angioplasty versus alteplase
(adjusted odds ratio, 0.62; 95% confidence interval, 0.41–0.96) with a similar trend for
diabetics (0.70, [0.29–1.72]). We noted no interaction between diabetic status and treatment
strategy on outcome (p 5 0.88).
CONCLUSIONS Primary angioplasty was similarly successful in diabetics and nondiabetics and appeared to be
more effective than thrombolytic therapy among diabetics with acute infarction. (J Am Coll
Cardiol 2000;35:1502–12) © 2000 by the American College of Cardiology
Diabetes mellitus independently predicts morbidity and
mortality after acute myocardial infarction (AMI) (1–15).
Although thrombolytic therapy has improved outcomes
among diabetics with AMI (16), their outcomes remain
unacceptably poor. The underlying mechanisms for these
poor outcomes are not clearly understood; diabetics under-
going thrombolysis in the Global Utilization of Streptoki-
nase and TPA (alteplase) for Occluded Coronary Arteries
(GUSTO-I) study had similarly-sized or smaller infarctions
compared with nondiabetics, similar 90-min patency rates,
comparable 30-day reinfarction rates and equivalent left
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ventricular systolic function, yet their adjusted 30-day mor-
tality was significantly higher (8). However, vital informa-
tion that could explain the worse outcome for diabetics is
lacking. For example, there are few data on angiographic
status before reperfusion therapy among diabetic and non-
diabetic patients.
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Primary angioplasty is an alternative strategy to achieve
reperfusion in AMI (17), but the effect of diabetic status on
angiographic and clinical outcomes of this strategy have not
been well documented. Primary angioplasty may be less
successful among diabetics owing to the more extensive
atherosclerosis, impaired microvascular autoregulation and
prothrombotic and vasospastic effects of diabetes (2,4).
The Global Use of Strategies To Open Occluded Arter-
ies in Acute Coronary Syndromes (GUSTO-IIb) Angio-
plasty Substudy is the largest randomized trial to compare
primary angioplasty with accelerated thrombolysis using
alteplase (18). In this substudy, short-term outcomes were
improved with primary angioplasty, and at six months the
two strategies were comparable. The present analysis of the
GUSTO-IIb Angioplasty Substudy cohort aimed to exam-
ine the impact of diabetic status on 1) the clinical and
angiographic characteristics of patients before and after
primary angioplasty and 2) the relative benefits of primary
angioplasty versus thrombolysis for AMI.
METHODS
GUSTO-IIb angioplasty substudy. The main GUSTO-
IIb trial was a prospective study of two adjunctive therapies,
heparin or hirudin, in patients with acute coronary syn-
dromes (19). The GUSTO-IIb Angioplasty Substudy (18)
also was designed to compare the efficacy of primary
angioplasty versus alteplase for AMI. In brief, 1,138 pa-
tients from Europe, North America and Australia were
enrolled prospectively from July 5, 1994, through January 1,
1996. Patients presenting within 12 h after symptom onset
(chest pain lasting $20 min with ST segment elevation
$2 mm in at least two contiguous leads or left bundle
branch block) were eligible. Criteria for exclusion were
previous stroke, active bleeding, contraindication to heparin,
serum creatinine . 177 mmol/L (.2.0 mg/dL), blood
pressure . 200 mm Hg systolic or . 110 mm Hg diastolic,
warfarin use at enrollment, ineligibility for angioplasty due
to lack of arterial access site, childbearing potential and prior
enrollment in GUSTO-II.
Eligible patients were randomized in a 2 3 2 factorial
design to either intravenous heparin (5,000-U bolus fol-
lowed by a three- to five-day infusion at 1,000 U/h) or
intravenous hirudin (0.1-mg/kg bolus followed by infusion
at 0.1 mg/kg/h for three to five days) and either primary
angioplasty or accelerated alteplase (15 mg intravenous
bolus followed by an infusion of 0.75 mg/kg over 30 min,
not to exceed 50 mg, then 0.50 mg/kg over the next hour,
not to exceed 35 mg). Heparin and hirudin infusions were
titrated to maintain an activated partial thromboplastin time
(aPTT) of 60 to 85 s. All patients received aspirin (160 mg
to be chewed at enrollment, followed by a daily dose of 80
to 325 mg); all other medications were given at the
discretion of the attending physician.
Primary angioplasty was performed according to local
standards, with the intent of reestablishing blood flow in the
infarct artery as soon as possible. Heparin or hirudin was
given after securing arterial access, but before angioplasty, at
a dose titrated to reach an activated clotting time (ACT)
$350 s. In general, the culprit artery was the only target.
After intervention, the study drug was stopped temporarily
to allow for sheath removal.
The Angiographic Core Laboratory analyzed cineangio-
grams with a validated edge-detection method (Artrek,
version 1.69, Quinton Imaging Systems, Bothell, Washing-
ton) (20). The following variables were recorded: pre- and
post-treatment Thrombolysis In Myocardial Infarction
(TIMI) flow grade, minimum luminal and reference diam-
eter dimensions and percent diameter stenosis within the
treated segment. Procedural success was defined as ,50%
residual diameter stenosis of the treated segment with TIMI
grade 3 flow. (Antegrade flow into the coronary bed distal to
the obstruction occurs as promptly as into the bed proximal
to the obstruction, and clearance of the contrast material
occurs as promptly as clearance of material from an unin-
volved bed in the same vessel or opposite artery.) Extent of
coronary artery disease before angioplasty was determined
by the number of major epicardial arteries with $70%
stenosis; multivessel disease was defined as $70% stenosis
in at least two major epicardial arteries or $50% stenosis of
the left main coronary artery.
Diabetes status. Diabetes mellitus was considered present
if a patient had been informed of this diagnosis and was on
prescribed treatment (diet, tablets or insulin). In the study
case report form, patients with diabetes mellitus were
further categorized based on insulin/noninsulin treatment.
Among the patients not receiving insulin, we did not record
whether the treatment was diet alone or diet and tablets.
End points. The primary end point of the GUSTO-IIb
Angioplasty Substudy (18) and of our analysis was a
composite of overall death, nonfatal reinfarction or nonfatal,
disabling stroke at 30 days, as confirmed by the clinical
events committee. Reinfarction was confirmed by follow-up
electrocardiogram and recurrent elevation of creatine kinase
and creatine kinase-myocardial band levels. Computerized
axial tomography or magnetic resonance imaging of the
brain was recommended for all patients with suspected
stroke. Ancillary end points included clinical event rates
during hospitalization and at six and 12 months. The
incidences of stroke and AMI were assessed only within the
Abbreviations and Acronyms
ACT 5 activated clotting time
AMI 5 acute myocardial infarction
aPTT 5 activated partial thromboplastin time
GUSTO-IIb 5 Global Use of Strategies To Open
Occluded Arteries in Acute Coronary
Syndromes (trial)-IIb
TIMI 5 Thrombolysis In Myocardial Infarction
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first 30 days and 180 days, respectively. Procedural success,
defined above, also was assessed among patients who were
randomized to and underwent angioplasty. This substudy
analysis was designed to detect a 40% relative reduction in
the primary end point (30-day death, nonfatal reinfarction
or nonfatal disabling stroke) with alpha 5 0.05 and beta 5
0.20 (or power 5 0.80).
Data analysis. All analyses were performed using SAS
software (SAS Institute, Cary, North Carolina). Continu-
ous variables were summarized as medians with 25th and
75th percentiles, and categorical variables as frequencies and
percentages. Prespecified baseline variables were compared
with the outcome variables of interest using chi-square tests
for categorical variables (likelihood ratio chi-square or
Fisher exact test and Cochran-Mantel-Haenszel test for
stratified tables). Analysis of variance was used to compare
the means of continuous variables, while the nonparametric
Wilcoxon rank-sum test was used to compare the distribu-
tions of ranked outcomes. For both diabetic and nondiabetic
groups, odds ratios with 95% confidence intervals were used
to compare treatments with regard to the primary end point,
under the intention-to-treat principle. Logistic regression
modeling was used to assess the relationships of treatment
assignment (angioplasty or alteplase) and diabetic status and
their interaction (if any) with the primary end point. The
baseline characteristics of interest are listed in Table 1.
Kaplan-Meier curves were also formulated to predict event-
free survival at six months (death or reinfarction) and at 12
months (death) for diabetic and nondiabetic patients, and
the curves were compared using the log-rank statistic. All
tests of significance were two-tailed. Differences between
groups were considered significant at p # 0.05.
RESULTS
Of the 1,138 patients enrolled in the GUSTO-IIb Angio-
plasty Substudy, 177 were diabetic (of whom 78 were
randomized to alteplase and 99 to angioplasty), and 961
were not diabetic (495 randomized to alteplase, 466 to
angioplasty). The randomized diabetic group comprised 47
(27%) insulin-treated diabetics and 128 (73%) noninsulin-
treated diabetics. Two diabetic patients had missing diabetic
treatment information.
Baseline demographic and clinical variables based on
diabetic status. The diabetic patients were older, were
more often women, weighed more and had a greater
frequency of hypertension and peripheral vascular disease
than nondiabetic patients (Table 1). Baseline systolic blood
pressure and heart rate were higher in diabetics. Current
smoking was more common among nondiabetics. The times
from symptom onset to hospital arrival, randomization and
treatment (angioplasty or alteplase) were significantly longer
for diabetics. In contrast, the time from arrival to treatment
was similar for both groups, although diabetics had a
slightly longer time to administration of alteplase after
randomization than nondiabetics. The proportions of dia-
betic and nondiabetic patients randomized to heparin or
hirudin were similar. The use of cardiac medications before
and after randomization was similar between groups, except
for a greater use before enrollment of beta-adrenergic
blocking agents and angiotensin-converting enzyme inhib-
itors in diabetics (Table 2).
Angiographic variables. Angiography was performed in
95 (96%) diabetics and 456 (98%) nondiabetics randomized
to angioplasty. Of these, 21 had coronary angiography .6 h
after enrollment: 4 (4.2%) diabetics and 17 (3.8%) nondia-
betics. Eventually 81 (82%) diabetics and 391 (84%) non-
diabetics underwent percutaneous intervention, of which
only one (1.2%) diabetic and four (1%) nondiabetics under-
went the procedure .6 h after enrollment. Thirteen pa-
tients randomized to coronary angioplasty were referred to
coronary bypass graft surgery within 24 h of the coronary
angiography.
In addition, 9 (9.1%) diabetic and 24 (5.2%) nondiabetic
patients randomized to angioplasty received thrombolytic
therapy. Ten of these patients underwent coronary angiog-
raphy and received thrombolytic therapy, and 23 received
thrombolytic therapy alone and did not undergo coronary
angiography.
Of the patients randomized to alteplase, 74 (95%) dia-
betics and 477 (96%) nondiabetics received this or another
thrombolytic agent. Angiography was later performed in 53
(68%) diabetics and 305 (62%) nondiabetics, and 20 (26%)
diabetics and 110 (22%) nondiabetics underwent interven-
tion. Angiography was performed within 6 h of enrollment
in 7 (14%) diabetics and 44 (16%) nondiabetics randomized
to alteplase.
Among the patients randomized to angioplasty who
underwent angiography, multivessel disease was more prev-
alent in diabetics than it was in nondiabetics (p 5 0.06,
Table 3). Left ventricular ejection fraction also was signif-
icantly lower in diabetics (p 5 0.003). The minimum
luminal diameter was smaller in diabetics (p 5 0.07), as was
the reference-segment diameter (p 5 0.08), resulting in a
greater percent diameter stenosis among diabetics (p 5
0.054). Although the distribution of initial TIMI flow
grades did not differ significantly between diabetics and
nondiabetics, 80.7% of diabetics had TIMI grade 0 or 1 flow
compared with 71.8% of nondiabetics (p 5 0.10). There was
no difference in culprit-artery distribution between groups.
Among the patients randomized to and undergoing
intervention, multivessel disease was more prevalent in
diabetics than it was in nondiabetics (p 5 0.01, Table 4).
Left ventricular ejection fraction also was lower in diabetics
(p 5 0.051). The minimum luminal diameter was smaller in
diabetics (p 5 0.06), as was the reference-segment diameter
(p 5 0.06), resulting in a greater percent diameter stenosis
among diabetics (p 5 0.09). A greater proportion of
diabetics than nondiabetics had TIMI grade 0 or 1 flow
before intervention (84% and 76%, respectively; p 5 0.12).
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There was no difference in culprit-artery distribution be-
tween groups. Balloon angioplasty alone was the major
modality used in both groups, and the procedure was equally
successful for diabetics and nondiabetics (success rates of
70.4% and 72.4%, respectively; p 5 0.79). Femoral vascular
bleeding complications were also similarly uncommon (p 5
0.98).
Of the patients randomized to angioplasty who under-
Table 1. Baseline Demographic and Clinical Variables
Diabetes
(n 5 177)
No Diabetes
(n 5 961) p Value
Age (yr) 64.8 (56.5, 70.9) 62.2 (51.1, 70.5) 0.01
$75 yrs 26 (14.7%) 135 (14.1%) NS
Female gender 59 (33.3%) 201 (20.9%) 0.0003
Weight (kg) 79.0 (68.0, 91.0) 75.0 (68.0, 85.0) 0.006
Height (cm) 170.0 (162.0, 176.0) 170.0 (165.0, 176.0) NS
Blood pressure (mm Hg)
Systolic 138 (120, 151) 130 (115, 145) 0.005
Diastolic 80 (70, 90) 80 (70, 90) NS
Heart rate (beats/min) 82 (69, 92) 73 (62, 85) 0.0001
Serum creatinine (mg/dL) 1.00 (0.9, 1.2) 1.01 (0.9, 1.2) NS
Killip class
I 159 (89.8%) 875 (91.2%) NS
II 16 (9.0%) 73 (7.6%)
III 0 (0.0%) 6 (0.6%)
IV 2 (1.1%) 6 (0.6%)
Peak creatine kinase (IU/mL) 1,460 (770, 2,838) 1,808 (878, 3,151) NS
Current anterior infarction 82 (46.9%) 417 (43.9%) NS
Hypercholesterolemia 64 (36.2%) 337 (35.1%) NS
Hypertension 100 (56.5%) 344 (35.8%) ,0.0001
Smoking
Current 56 (31.8%) 434 (45.6%) 0.003
Previous 55 (31.3%) 239 (25.1%)
Never 65 (36.9%) 279 (29.3%)
Peripheral vascular disease 19 (10.7%) 50 (5.2%) 0.009
Prior infarction 33 (18.6%) 125 (13.1%) NS
Prior angina 75 (42.4%) 379 (39.4%) NS
Prior angioplasty 5 (2.8%) 52 (5.4%) NS
Prior bypass surgery 8 (4.5%) 20 (2.1%) NS
Prior heart failure 4 (2.3%) 14 (1.5%) NS
Family history of coronary disease 50 (28.3%) 318 (33.1%) NS
Min from symptom onset to arrival 133 (85, 228) 110 (63, 183) 0.0005
Alteplase 125 (90, 182) 107 (60, 190) 0.03
Angioplasty 149 (79, 244) 110 (65, 176) 0.007
Min from symptom onset to
randomization
190 (131, 285) 152 (102, 240) 0.0001
Min from symptom onset to
treatment*
231 (170, 334) 200 (145, 285) 0.0005
Alteplase 200 (150, 265) 180 (120, 259) 0.06
Angioplasty 281 (210, 400) 224 (178, 312) 0.002
Min from arrival to treatment
Alteplase 67 (45, 107) 65 (45, 100) NS
Angioplasty 135 (106, 163) 124 (102, 151) NS
Min from randomization to treatment*
Alteplase 25 (20, 35) 20 (15, 32) 0.04
Angioplasty 75 (59, 100) 76 (62, 95) NS
Adjunctive anticoagulation
Hirudin 84 (50.6%) 436 (51.5%) NS
Heparin 82 (49.4%) 410 (48.5%) NS
*Start of thrombolytic therapy or angioplasty balloon inflation. Data presented are median (25th, 75th percentiles) or number
(%) of patients.
NS 5 not significant.
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went angiography, 14 diabetics and 65 nondiabetics did not
undergo angioplasty (Table 5). These patients either had
severe coronary artery disease or, conversely, had a patent
artery. Indeed, large proportions of both groups had TIMI
grade 3 flow. Of the 79 patients, 19 patients underwent
bypass surgery: 5 diabetics and 14 nondiabetics.
Coagulation variables. Maximum ACT values during an-
gioplasty did not differ significantly between groups (Table
6). In addition, aPTTs for patients randomized to and
undergoing angioplasty were similar at all intervals within
48 h for diabetics and nondiabetics. The aPTT values
among nondiabetics randomized to alteplase were higher at
6 h and 48 h.
In-hospital outcomes. The frequency of major in-hospital
adverse outcomes was similar for diabetics and nondiabetics,
regardless of treatment strategy (Table 7), except that both
in-hospital heart failure and cardiogenic shock were more
common among diabetics (p 5 0.001 and p 5 0.04,
respectively). Diabetic patients undergoing angioplasty had
a significantly greater incidence of bleeding complications
compared with those receiving thrombolytic therapy.
Reperfusion by angioplasty was associated with a significant
reduction in the occurrence of in-hospital recurrent isch-
emia compared with alteplase for both diabetics (13.1% vs.
29.5%, p 5 0.007) and nondiabetics (14.1% vs. 23.1%, p ,
0.001). There was a significant interaction between diabetic
status and treatment strategy with respect to the occurrence
of in-hospital recurrent ischemia (p , 0.001). There was
also an interaction between diabetic status and treatment
strategy on in-hospital refractory ischemia, although it did
not reach statistical significance (p 5 0.07). The duration of
hospital stay for diabetics did not differ after either alteplase
or angioplasty, but nondiabetic patients spent a median one
less day in the hospital after angioplasty versus alteplase
(p 5 0.0001).
30-day outcomes. For the whole population, the compos-
ite 30-day outcome occurred less often with angioplasty
than with alteplase, irrespective of diabetic status (p 5 0.03,
Table 8). Primary angioplasty also was associated with
better overall adjusted outcome (adjusted odds ratio, 0.63;
95% confidence interval, 0.43–0.93). The composite 30-day
end point of death, nonfatal reinfarction or nonfatal, dis-
abling stroke was reached in 24 of 171 diabetics (13.6%) and
in 108 of 961 nondiabetics (11.2%; adjusted odds ratio,
Table 2. Baseline and In-hospital Use of Cardiac Medications
Diabetes
(n 5 177)
No
Diabetes
(n 5 961)
p
Value
Baseline medications
Aspirin 64.3 62.0 NS
Beta-blockers 35.8 27.1 0.06
Nitrates 74.3 69.8 NS
Calcium-channel blocker 57.6 49.6 NS
ACE inhibitors 21.6 11.6 0.02
In-hospital medications
Aspirin 88.3 89.4 NS
Beta-blockers 82.5 82.2 NS
Nitrates 60.1 54.2 NS
Calcium-channel blockers 39.0 50.6 NS
ACE inhibitors 85.2 88.6 NS
Data presented are percentages.
ACE 5 angiotensin-converting enzyme.
Table 3. Initial Angiographic Data for Patients Randomized to Angioplasty
Diabetes
(n 5 95)
No Diabetes
(n 5 456) p Value
Extent of coronary artery disease 0.06
Single 48 (50.5%) 287 (63.2%)
Multivessel 43 (45.3%) 147 (32.4%)
None 1 (1.1%) 11 (2.4%)
Culprit coronary artery 0.43
Left anterior descending 42 (44.2%) 186 (40.8%)
Left circumflex 8 (8.4%) 59 (12.9%)
Right coronary 39 (41.1%) 190 (41.7%)
Other 5 (5.3%) 12 (2.6%)
Ejection fraction (%) 48 (38, 55) 51 (44, 61) 0.003
Minimum luminal diameter (mm) 0 (0, 0) 0 (0, 0.54) 0.07
Reference-segment diameter (mm) 2.5 (2.1, 3.1) 2.7 (2.3, 3.1) 0.08
Percent stenosis 100 (99, 100) 100 (80.4, 100) 0.054
TIMI flow grade 0.40
0 60 (68.2%) 248 (58.8%)
1 11 (12.5%) 55 (13.0%)
2 12 (13.6%) 84 (19.9%)
3 5 (5.7%) 35 (8.3%)
Data presented are median (25th, 75th percentiles) or number (%) of patients.
TIMI 5 Thrombolysis in Myocardial Infarction.
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1.12, 95% confidence interval, 0.68–1.84). The advantage
of angioplasty over thrombolysis was similar among patients
with (adjusted odds ratio, 0.70; 95% confidence interval,
0.29–1.72) and without diabetes (adjusted odds ratio, 0.62;
95% confidence interval, 0.41–0.96). Indeed, the impact of
treatment strategy on the 30-day composite outcome was
not affected significantly by diabetic status (p 5 0.88). For
each reperfusion strategy (alteplase vs. angioplasty), after
controlling for diabetic status, the incidence of the compos-
ite outcome was similar for patients assigned to heparin or
hirudin (test for interaction, adjusted p 5 0.17).
Six-month death/reinfarction. Within six months of
follow-up after AMI (Fig. 1), there was no significant differ-
ence in the cumulative incidence of death/reinfarction between
diabetic and nondiabetic patients (p 5 0.18 using the log-rank
statistic). Among the diabetic patients, there was no difference
between those randomized to angioplasty versus thrombolytic
therapy (p 5 0.48), with a similar trend for nondiabetics (p 5
0.52). Among patients who had TIMI 3 flow post-angioplasty,
there was no difference in six-month survival free of death/
reinfarction between diabetics and nondiabetics (estimated
event-free survival of 0.93 6 0.03 and 0.91 6 0.02, respec-
tively; p 5 0.55). Likewise, six-month event-free survival was
similarly poor for patients who did not achieve TIMI 3 flow
(estimated event-free survival of 0.75 6 0.08 and 0.83 6 0.04,
respectively; p 5 0.33).
Table 4. Angiographic and Procedural Data for Patients Randomized to Angioplasty Who
Underwent Intervention
Diabetes
(n 5 81)
No Diabetes
(n 5 391) p Value
Extent of coronary artery disease 0.01
Single 43 (53.1%) 259 (66.2%)
Multivessel 35 (43.2%) 125 (32.0%)
None 0 1 (0.3%)
Culprit coronary artery 0.97
Left anterior descending 37 (45.7%) 159 (40.7%)
Left circumflex 8 (9.9%) 52 (13.3%)
Right coronary 33 (40.7%) 177 (45.3%)
Other 3 (3.7%) 3 (0.8%)
Ejection fraction (%) 48 (40, 56) 51 (44, 60) 0.051
Minimum luminal diameter (mm) 0 (0, 0) 0 (0, 0.41) 0.06
Reference-segment diameter (mm) 2.5 (2.1, 3.1) 2.7 (2.3, 3.1) 0.06
Percent stenosis before intervention 100 (99, 100) 100 (84.5, 100) 0.09
TIMI flow grade before intervention 0.12
0 55 (70.5%) 236 (62.1%)
1 11 (14.1%) 53 (14.0%)
2 9 (11.5%) 71 (18.7%)
3 3 (3.9%) 20 (5.3%)
Type of intervention 0.70
Angioplasty 74 (91.4%) 361 (92.3%)
With stenting 7 (8.6%) 26 (6.7%)
With atherectomy 0 2 (0.5%)
Stenting alone 0 1 (0.3%)
Atherectomy alone 0 0
Other 0 1 (0.3%)
Successful angioplasty 57 (70.4%) 283 (72.4%) 0.79
TIMI flow grade after intervention 0.14
0 5 (6.4%) 9 (2.4%)
1 0 5 (1.3%)
2 16 (20.5%) 69 (18.2%)
3 57 (73.1%) 296 (78.1%)
Residual diameter stenosis $50% 16 (21.9%) 82 (22.3%) 1.0
Femoral vascular access bleeding 0.98
None 57 (70.4%) 272 (69.7%)
Mild 21 (25.9%) 104 (26.7%)
Moderate 2 (2.5%) 12 (3.1%)
Severe 1 (1.2%) 2 (0.5%)
Data presented are median (25th, 75th percentiles) or number (%) of patients.
TIMI 5 Thrombolysis in Myocardial Infarction.
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12-month survival. Mortality within 12 months after
AMI (Fig. 2) was marginally higher among diabetic than
nondiabetic patients (p 5 0.09). After adjusting for differ-
ences in baseline variables, the odds ratio of death within 12
months for diabetics was 1.34 (95% confidence interval,
0.78–2.31). Mortality within 12 months was not signifi-
cantly different among both diabetics and nondiabetics
randomized to angioplasty compared with alteplase (p 5
0.95 and p 5 0.47, respectively, using the log-rank statistic).
Among patients who had TIMI 3 flow post-angioplasty,
there was no difference in 12-month survival between
diabetics and nondiabetics (estimated survival of 0.98 6
0.02 and 0.95 6 0.01, respectively; p 5 0.90). Likewise,
12-month survival was similarly poor for patients who did
not achieve TIMI 3 flow (estimated survival of 0.77 6 0.08
and 0.86 6 0.03, respectively; p 5 0.25).
Diabetic treatment strategy and outcome. Of the 78
diabetic patients who were randomized to alteplase, 22 were
insulin-treated and 55 were treated by diet with or without
tablets (one patient had unknown treatment status). The
primary end point was reached in 18.2% and 14.6% of
insulin- and noninsulin-treated patients, respectively (p 5
NS). Of the 99 diabetic patients randomized to angioplasty,
25 were insulin-treated and 73 were treated by diet with or
without tablets (one patient had unknown treatment status).
The primary end point was reached in 4.0% and 13.7% of
insulin- and noninsulin-treated patients, respectively (p 5
Table 5. Angiographic Data for Patients Randomized to Angioplasty Who Did Not Undergo
Intervention
Diabetes
(n 5 14)
No Diabetes
(n 5 65) p Value
Extent of coronary artery disease 0.35
Single 5 (35.7%) 28 (44.4%)
Multivessel 8 (57.1%) 22 (34.9%)
None 1 (7.1%) 10 (15.9%)
Culprit coronary artery 0.51
Left anterior descending 5 (35.7%) 27 (41.5%)
Left circumflex 0 7 (10.8%)
Right coronary 6 (42.9%) 13 (20%)
Other 2 (14.3%) 9 (13.9%)
Ejection fraction (%) 40 (35, 48) 51 (44.5, 65.8) 0.012
Minimum luminal diameter (mm) 0.25 (0, 0.79) 0.60 (0, 1.15)
Reference-segment diameter (mm) 2.6 (2.1, 2.9) 2.4 (2.2, 3.0) 0.92
Percent stenosis 91.5 (65, 100) 74.5 (54.4, 100) 0.17
TIMI flow grade 0.22
0 5 (50%) 12 (28.6%)
1 0 2 (4.8%)
2 3 (30%) 13 (31%)
3 2 (20%) 15 (37%)
Data presented are median (25th, 75th percentiles) or number (%) of patients.
TIMI 5 Thrombolysis in Myocardial Infarction.
Table 6. Coagulation Data According to Diabetic Status
Diabetes No Diabetes p Value
Angioplasty (n 5 72) (n 5 354)
Maximum procedural ACT (s) 381 (313, 517) 379 (324, 477) 0.97
aPTT (s) (n 5 75) (n 5 367)
6 h 92 (58, 150) 102 (69, 150) 0.18
12–16 h 62 (52, 87) 71 (54, 101) 0.22
24 h 53 (41, 68) 48 (35, 67) 0.09
48 h 60 (49, 76) 63 (48, 78) 0.44
Alteplase
aPTT (s) (n 5 70) (n 5 439)
6 h 78 (50, 96) 84 (62, 120) 0.04
12–16 h 72 (52, 92) 75 (59, 94) 0.18
24 h 67 (49, 78) 67 (53, 83) 0.42
48 h 59 (49, 69) 65 (53, 78) 0.02
Data presented are median (25th, 75th percentiles).
ACT 5 activated clotting time; aPTT 5 activated partial thromboplastin time.
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NS). We did not find an interaction between diabetic
treatment strategy and reperfusion strategy (alteplase vs.
angioplasty) with respect to outcome.
DISCUSSION
The principal finding of this analysis from the GUSTO-IIb
Angioplasty Substudy was that outcomes in-hospital, at 30
days and at 6 and 12 months were better among diabetics
randomized to primary angioplasty compared with those
randomized to accelerated alteplase. Despite the worse
clinical and angiographic profiles of diabetics upon presen-
tation, primary angioplasty was similarly successful among
diabetics and nondiabetics. Therefore, similar to patients
without diabetes, this strategy should be contemplated as an
alternative reperfusion strategy for diabetics presenting with
AMI.
Diabetes and factors before reperfusion therapy. Our
study highlights two important pretreatment factors that
may partly explain the worse outcomes of diabetics reported
in prior studies. The first, the significant delay from symp-
tom onset to hospital arrival, results in a significant delay in
the administration of reperfusion treatment. This has been
reported in other trials (7,8,20–22) and may partially reflect
the difficulty in interpreting the electrocardiograms of dia-
betic patients, who frequently have complex coronary artery
disease. In addition, the presenting symptoms of diabetic
patients may be more difficult to relate to active ischemic
heart disease.
Table 7. In-hospital Events
Diabetes No Diabetes
p
Value*
Alteplase
(n 5 78)
Angioplasty
(n 5 99)
p
Value
Alteplase
(n 5 495)
Angioplasty
(n 5 466)
p
Value
Death 4 (5.1%) 9 (9.1%) 0.32 29 (5.9%) 23 (5.0%) 0.53 0.90
Heart failure 7 (9.0%) 10 (10.1%) 0.80 21 (4.3%) 14 (3.0%) 0.31 0.48
Cardiogenic shock 5 (6.4%) 10 (10.1%) 0.38 21 (4.3%) 24 (5.2%) 0.50 0.31
Stroke 1 (1.3%) 0 (0.0%) 0.26 8 (1.6%) 5 (1.1%) 0.47 0.32
Reinfarction 5 (6.4%) 2 (2.0%) 0.14 24 (4.9%) 16 (3.5%) 0.28 0.12
Recurrent ischemia 23 (29.5%) 13 (13.1%) 0.007 114 (23.1%) 65 (14.1%) , 0.001 , 0.001
Refractory ischemia 7 (9.0%) 3 (3.0%) 0.09 22 (4.5%) 14 (3.0%) 0.25 0.07
Moderate/severe bleeding 6 (7.7%) 18 (18.2%) 0.04 48 (9.7%) 51 (9.1%) 0.52 0.15
Emergency bypass surgery 7 (9.0%) 10 (10.1%) 0.80 40 (8.1%) 32 (6.9%) 0.47 0.58
Hospital stay (days) 10 (7, 17) 9 (6, 14) 0.22 9 (7, 13) 8 (5, 11) 0.0001 0.60
*Comparison of effect of diabetic status on treatment strategy (alteplase vs. angioplasty). Data presented are median (25th, 75th percentiles) or number (%) of patients.
Recurrent ischemia: symptoms, electrocardiogram changes or new hypotension, pulmonary edema or murmur thought by the physician to represent myocardial ischemia.
Refractory ischemia: defined symptoms of ischemia with ST segment deviation or definite T wave inversion .12 h after enrollment, which lasts .10 min, despite use of nitrates
and either beta-blockers or calcium channel blockers and not fulfilling criteria for myocardial infarction. All refractory ischemia is also recurrent ischemia.
Table 8. Events at 30 Days and OR
Alteplase Angioplasty
Unadjusted OR
(95% CI)
Adjusted* OR
(95% CI)
All patients (n 5 573) (n 5 565)
Death 40 (7.0%) 32 (5.7%)
Reinfarction 37 (6.5%) 25 (4.5%)
Disabling stroke 11 (1.9%) 6 (1.1%)
Composite 78 (13.7%) 54 (9.6%) 0.67 (0.46–0.97) 0.63 (0.43–0.93)
Diabetic patients (n 5 78) (n 5 99)
Death 5 (6.4%) 8 (8.1%)
Reinfarction 8 (10.3%) 3 (3.0%)†
Disabling stroke 2 (2.6%) 0 (0.0%)
Composite 13 (16.7%) 11 (11.1%) 0.63 (0.26–1.48) 0.70 (0.29–1.72)
Nondiabetic patients (n 5 495) (n 5 466)
Death 35 (7.1%) 24 (5.2%)
Reinfarction 29 (5.9%) 22 (4.8%)
Disabling stroke 9 (1.8%) 6 (1.3%)
Composite 65 (13.2%) 43 (9.3%) 0.67 (0.45–1.0) 0.62 (0.41–0.96)
*Adjusted for age, baseline Killip class, previous infarction, previous congestive heart failure and height; †p 5 0.05 for angioplasty
vs. alteplase in diabetics.
CI 5 confidence interval; OR 5 odds ratio.
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The second factor is the significantly worse angiographic
features of the culprit artery before reperfusion therapy.
Current knowledge about the effect of diabetes on the
angiographic characteristics of patients with AMI is based
primarily on data derived from trials in which angiography
was performed after thrombolysis. Our data are unique in
that angiography was performed before reperfusion therapy
in a large proportion of patients. Our findings show that
before reperfusion treatment, diabetics have a higher inci-
dence of TIMI grade 0 or 1 flow and more severe stenosis
of the culprit artery than do nondiabetics.
Several possible mechanisms may explain the relatively
greater stenosis of the culprit artery and worse flow among
diabetics before reperfusion therapy. First, as mentioned
above, there are significant delays until hospital arrival and
treatment among diabetics. Thus, by the time reperfusion
therapy is contemplated for diabetics, the occluding throm-
bus may be in advanced stages of organization. In addition,
diabetics have increased platelet aggregatory and procoagu-
lant activity, leading to an inherently greater incidence and
rate of thrombus formation (2,11). The dynamic balance
between thrombosis and endogenous fibrinolysis probably is
shifted toward accelerated thrombosis in diabetics (4,11),
possibly due to 1) the enhanced activation, adhesion and
aggregation of platelets, 2) elevated levels of circulating
procoagulant factors (such as fibrinogen, von Willebrand
factor, Factor VII) and 3) impaired endogenous fibrinolysis
secondary to elevation in plasminogen activator inhibitor-1
Figure 1. Kaplan-Meier curves depicting the estimated survival free of death or reinfarction for diabetic and nondiabetic patients within
six months of follow-up after (Re) MI. (Re) MI 5 reinfarction.
Figure 2. Kaplan-Meier curves depicting the estimated survival for diabetic and nondiabetic patients within 12 months of follow-up after
(Re) MI. (Re) MI 5 reinfarction.
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levels (2,4,11,23). Last, the severity of atherosclerosis at the
site of occlusion may be greater among diabetics.
Diabetes and primary angioplasty. Due to the more
extensive atherosclerosis, impaired microvascular autoregu-
lation and prothrombotic and vasospastic effects of diabetes
(2,4), angioplasty might be expected to be less effective in
achieving adequate reperfusion in diabetics. Moreover, di-
abetics more often have complex lesions underlying the site
of plaque rupture (24). However, we saw no difference in the
proportions of diabetics and nondiabetics achieving a suc-
cessful primary angioplasty result (TIMI grade 3 flow and
,50% residual stenosis in 70.4% of diabetics and 72.4% of
nondiabetics). However, moderate/severe bleeding compli-
cations were more prevalent among diabetics. Thus, primary
angioplasty appears to be an effective method to achieve
reperfusion among diabetics at the cost of increased bleed-
ing complications.
Thrombolysis versus angioplasty for diabetics. Our sub-
group analysis highlights several potential advantages of
primary angioplasty over thrombolytic therapy for diabetics.
As mentioned, primary angioplasty may reduce the time to
reperfusion for diabetics compared with thrombolytic ther-
apy. In addition, a strategy of primary angioplasty can
promptly identify patients with worse left ventricular func-
tion and more extensive disease who benefit most from
bypass surgery. Indeed, a larger proportion of diabetics in
our cohort was referred to bypass surgery after angiography
for precisely these reasons.
More important, primary angioplasty may be particularly
effective in reducing recurrent ischemia and reinfarction
among diabetics, which can be associated with additional
mortality, morbidity and resource use in the long term (25).
The benefits of primary angioplasty among diabetics may
lessen over longer-term follow-up, however. Diabetes mel-
litus is associated with increased restenosis after balloon
angioplasty and stent implantation (26–31). Because resten-
osis may occur more than six months after intervention, the
difference in the recurrent ischemia rates between the
groups in our study may subsequently have diminished.
Of note, up to six months after the acute event, primary
angioplasty did not result in a survival benefit for diabetics
when compared with thrombolytic therapy. Indeed, the
incidence of death was greater among diabetics randomized
to angioplasty. Possibly, because of the complexity of the
coronary lesions in diabetics, primary angioplasty is associ-
ated with an early hazard ratio. However, at 12-month
follow-up, both strategies resulted in similar survival among
diabetics.
Study limitations. Several issues should be considered in
interpreting these findings. In this study, the relationship of
diabetic status and outcome after primary angioplasty was
evaluated in patients with ST segment elevation or new left
bundle branch block who were eligible to receive thrombo-
lytic therapy. For patients presenting with other ST or T
segment abnormalities, and for patients ineligible to receive
thrombolytic therapy, the effect of diabetes on outcomes of
reperfusion strategies may differ. Moreover, because diabetic
cardiomyopathy and autonomic imbalance may predispose
to arrhythmia, congestive heart failure and cardiogenic
shock, diabetics may be more prone to prehospital sudden
death than nondiabetics (2). Our data about angiographic
characteristics before reperfusion therapy pertain only to
patients who survived the initial phases of AMI. Another
limitation of this study was the relatively short follow-up. In
addition, owing to the advent of interventional cardiology
techniques since this study was performed, including the use
of intracoronary stents and antiplatelet therapy, the results
in the angioplasty arm of our study may be an underesti-
mation of current success rates (novel antiplatelet agents,
however, may also improve outcome of thrombolytic ther-
apy). Moreover, in our cohort, 10 patients received throm-
bolytic therapy after coronary angiography had been per-
formed, presumably because of angiographic evidence of
intracoronary thrombi. With the current widespread use of
intracoronary stents and platelet glycoprotein IIb/IIIa in-
hibitors, these lesions would likely be treated percutaneously
in current clinical practice. Thrombolysis in Myocardial
Infarction 3 flow was achieved in only 83% of patients in our
cohort, a significantly lower rate than in most prior studies.
While this may reflect variability in core lab definition of
TIMI 3 flow, it also raises the possibility that, with better
angioplasty results, the relative benefit of angioplasty would
be greater. Our analysis was also not a sterile comparison
between two therapeutic strategies. A minority of patients
randomized to angioplasty did not receive the assigned
treatment (i.e., approximately 3% of patients randomized to
angioplasty did not even undergo coronary angiography,
and 6% of patients randomized to angioplasty received
thrombolytic therapy either alone or after coronary angiog-
raphy had been performed). Likewise, approximately 15% of
patients randomized to alteplase underwent coronary an-
giography within 6 h of enrollment. Although this may
slightly confound our results, our analyses were based on the
intention-to-treat principle. These findings may be a truer
reflection of the “real-world situation,” in which coronary
angiography or percutaneous coronary interventions are not
performed at times, either because of logistic difficulties or
because the individual operator considers the culprit lesion
either too complex or unsuitable for intervention. In addi-
tion, there may be clinical evidence of reperfusion (resolu-
tion of pain or regression of ST segment elevation) before
thrombolytic therapy or coronary angioplasty are initiated,
obviating the need for pharmacological or mechanical reper-
fusion. These deviations from the study protocol, therefore,
should not be viewed as severe flaws in the study, but rather
a more accurate portrait of common clinical practice in the
years 1994 through 1996. Finally, because patients were not
randomized according to diabetic status, this study has
limitations applicable to all subgroup analyses of random-
ized trials. For a more definitive answer concerning the
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relationship of diabetes and reperfusion strategy, a specifi-
cally designed study is needed.
Conclusions. In the GUSTO-IIb Angioplasty Substudy
cohort, primary angioplasty was more effective than throm-
bolytic therapy among diabetics and nondiabetics with
AMI. Angiographic success after angioplasty was achieved
in similar proportions of diabetics and nondiabetics. There-
fore, as with patients without diabetes, primary angioplasty
should be contemplated as an alternative reperfusion strat-
egy for diabetics presenting with AMI, if it can be per-
formed promptly by an experienced operator.
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